AU2014233048B2 - Magnetoencephalography biomarkers of GABA-B agonist drug activity in autism spectrum disorders - Google Patents
Magnetoencephalography biomarkers of GABA-B agonist drug activity in autism spectrum disorders Download PDFInfo
- Publication number
- AU2014233048B2 AU2014233048B2 AU2014233048A AU2014233048A AU2014233048B2 AU 2014233048 B2 AU2014233048 B2 AU 2014233048B2 AU 2014233048 A AU2014233048 A AU 2014233048A AU 2014233048 A AU2014233048 A AU 2014233048A AU 2014233048 B2 AU2014233048 B2 AU 2014233048B2
- Authority
- AU
- Australia
- Prior art keywords
- subject
- asd
- activity
- stimulus
- age
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000029560 autism spectrum disease Diseases 0.000 title claims abstract description 150
- 238000002582 magnetoencephalography Methods 0.000 title claims description 42
- 239000003814 drug Substances 0.000 title claims description 4
- 229940079593 drug Drugs 0.000 title claims description 3
- 230000000694 effects Effects 0.000 title description 88
- 239000000090 biomarker Substances 0.000 title description 5
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 55
- 230000004044 response Effects 0.000 claims description 53
- 238000002560 therapeutic procedure Methods 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 25
- 230000007177 brain activity Effects 0.000 claims description 14
- 150000003384 small molecules Chemical class 0.000 claims description 4
- 230000000144 pharmacologic effect Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 abstract description 15
- 208000025966 Neurological disease Diseases 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 description 34
- 206010003805 Autism Diseases 0.000 description 27
- 208000020706 Autistic disease Diseases 0.000 description 27
- 230000000763 evoking effect Effects 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 23
- 230000001965 increasing effect Effects 0.000 description 22
- 210000004885 white matter Anatomy 0.000 description 21
- 102100025488 CUGBP Elav-like family member 4 Human genes 0.000 description 20
- 101710170352 CUGBP Elav-like family member 4 Proteins 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 18
- 230000003247 decreasing effect Effects 0.000 description 16
- 230000006735 deficit Effects 0.000 description 14
- 230000003534 oscillatory effect Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 230000005855 radiation Effects 0.000 description 12
- 230000003993 interaction Effects 0.000 description 11
- 230000001537 neural effect Effects 0.000 description 11
- 210000003926 auditory cortex Anatomy 0.000 description 9
- 230000003111 delayed effect Effects 0.000 description 9
- 238000002598 diffusion tensor imaging Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 230000035800 maturation Effects 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 7
- 210000001153 interneuron Anatomy 0.000 description 7
- 230000010355 oscillation Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- KPYSYYIEGFHWSV-QMMMGPOBSA-N Arbaclofen Chemical compound OC(=O)C[C@@H](CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-QMMMGPOBSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000000946 synaptic effect Effects 0.000 description 5
- 230000003461 thalamocortical effect Effects 0.000 description 5
- 238000012935 Averaging Methods 0.000 description 4
- 230000000193 eyeblink Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001785 maturational effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012421 spiking Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 102000001675 Parvalbumin Human genes 0.000 description 3
- 108060005874 Parvalbumin Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 210000001926 inhibitory interneuron Anatomy 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000023105 myelination Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 230000001755 vocal effect Effects 0.000 description 3
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
- 208000029726 Neurodevelopmental disease Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 201000007197 atypical autism Diseases 0.000 description 2
- 230000002146 bilateral effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 125000000837 carbohydrate group Chemical group 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 125000003473 lipid group Chemical group 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- -1 small molecule compounds Chemical class 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 210000003478 temporal lobe Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000035976 Developmental Disabilities Diseases 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000006289 Rett Syndrome Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229950006826 arbaclofen Drugs 0.000 description 1
- 210000003984 auditory pathway Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000024825 childhood disintegrative disease Diseases 0.000 description 1
- 230000036992 cognitive tasks Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000010292 electrical insulation Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000008155 medical solution Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 230000007230 neural mechanism Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003957 neurotransmitter release Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000001176 projection neuron Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- 208000013406 repetitive behavior Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 230000005236 sound signal Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000009424 underpinning Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/242—Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents
- A61B5/245—Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals
- A61B5/246—Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals using evoked responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/40—Detecting, measuring or recording for evaluating the nervous system
- A61B5/4076—Diagnosing or monitoring particular conditions of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Neurosurgery (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787077P | 2013-03-15 | 2013-03-15 | |
| US61/787,077 | 2013-03-15 | ||
| PCT/US2014/030138 WO2014145382A2 (en) | 2013-03-15 | 2014-03-17 | Magnetoencephalography biomarkers of gaba-b agonist drug activity in autism spectrum disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2014233048A1 AU2014233048A1 (en) | 2015-10-08 |
| AU2014233048B2 true AU2014233048B2 (en) | 2019-01-03 |
Family
ID=51538466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014233048A Active AU2014233048B2 (en) | 2013-03-15 | 2014-03-17 | Magnetoencephalography biomarkers of GABA-B agonist drug activity in autism spectrum disorders |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10342480B2 (enExample) |
| EP (1) | EP2967405A4 (enExample) |
| JP (1) | JP6585030B2 (enExample) |
| AU (1) | AU2014233048B2 (enExample) |
| CA (1) | CA2907494C (enExample) |
| WO (1) | WO2014145382A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018194959A1 (en) * | 2017-04-17 | 2018-10-25 | Miron Oren | Auditory brainstem response for autism prediction |
| US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| US11426073B2 (en) * | 2018-04-27 | 2022-08-30 | Washington University | Imaging nerve function and pathologies using diffusion basis spectrum imaging |
| WO2020056418A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| FI20185893A1 (fi) * | 2018-10-23 | 2020-04-24 | Elekta Oy | Päähän asennettava laitteisto |
| US11103171B2 (en) * | 2018-10-23 | 2021-08-31 | BlackThor Therapeutics, Ine. | Systems and methods for screening, diagnosing, and stratifying patients |
| WO2020186148A1 (en) | 2019-03-13 | 2020-09-17 | The Children's Hospital Of Philadelphia | Methods for the detection of brain injury |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| WO2021096946A1 (en) * | 2019-11-15 | 2021-05-20 | The University Of Chicago | Cancer detection based on four quadrant mapping and matrix analysis of image data |
| US20230210425A1 (en) * | 2022-01-05 | 2023-07-06 | Tdk Corporation | Methods and Devices for Electromagnetic Measurements from Ear Cavity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2540295A1 (en) * | 2011-06-27 | 2013-01-02 | Centre national de la recherche scientifique | Compositions for the treatment of Fragile X syndrome |
-
2014
- 2014-03-17 AU AU2014233048A patent/AU2014233048B2/en active Active
- 2014-03-17 US US14/776,168 patent/US10342480B2/en active Active
- 2014-03-17 EP EP14762871.3A patent/EP2967405A4/en not_active Ceased
- 2014-03-17 CA CA2907494A patent/CA2907494C/en active Active
- 2014-03-17 WO PCT/US2014/030138 patent/WO2014145382A2/en not_active Ceased
- 2014-03-17 JP JP2016503336A patent/JP6585030B2/ja active Active
Non-Patent Citations (1)
| Title |
|---|
| GANDAL ET AL., "Validating oscillations and delayed auditory responses as translational biomarkers of autism.", BIOL PSYCHIATRY., (2010-12-15), vol. 68, no. 12, pages 1100 - 1106 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20160022207A1 (en) | 2016-01-28 |
| AU2014233048A1 (en) | 2015-10-08 |
| CA2907494A1 (en) | 2014-09-18 |
| WO2014145382A2 (en) | 2014-09-18 |
| WO2014145382A8 (en) | 2014-12-31 |
| EP2967405A2 (en) | 2016-01-20 |
| US10342480B2 (en) | 2019-07-09 |
| WO2014145382A3 (en) | 2014-10-30 |
| EP2967405A4 (en) | 2017-01-11 |
| CA2907494C (en) | 2022-10-04 |
| JP6585030B2 (ja) | 2019-10-02 |
| JP2016519595A (ja) | 2016-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014233048B2 (en) | Magnetoencephalography biomarkers of GABA-B agonist drug activity in autism spectrum disorders | |
| Edgar et al. | Neuromagnetic oscillations predict evoked-response latency delays and core language deficits in autism spectrum disorders | |
| Grent et al. | 40-Hz auditory steady-state responses characterize circuit dysfunctions and predict clinical outcomes in clinical high-risk for psychosis participants: a magnetoencephalography study | |
| Kim et al. | Diagnostic utility of quantitative EEG in un-medicated schizophrenia | |
| Roberts et al. | Maturational differences in thalamocortical white matter microstructure and auditory evoked response latencies in autism spectrum disorders | |
| Hata et al. | Functional connectivity assessed by resting state EEG correlates with cognitive decline of Alzheimer’s disease–An eLORETA study | |
| Edgar et al. | Cortical thickness as a contributor to abnormal oscillations in schizophrenia? | |
| Minshew et al. | Neurologic aspects of autism | |
| Javitt et al. | Neurophysiological biomarkers for drug development in schizophrenia | |
| Huneau et al. | Altered dynamics of neurovascular coupling in CADASIL | |
| Shin et al. | Pre-attentive auditory processing in ultra-high-risk for schizophrenia with magnetoencephalography | |
| Joseph et al. | Dorsolateral prefrontal cortex excitability abnormalities in Alzheimer's dementia: findings from transcranial magnetic stimulation and electroencephalography study | |
| Waninger et al. | Event-related potentials during sustained attention and memory tasks: Utility as biomarkers for mild cognitive impairment | |
| Zhou et al. | A modality‐specific dysfunction of pain processing in schizophrenia | |
| Boshra et al. | On the time-course of functional connectivity: theory of a dynamic progression of concussion effects | |
| Nguyen et al. | Electrophysiological measures as potential biomarkers in Huntington's disease: review and future directions | |
| Baumgarten et al. | Connecting occipital alpha band peak frequency, visual temporal resolution, and occipital GABA levels in healthy participants and hepatic encephalopathy patients | |
| Wu et al. | Resting-state electroencephalography of neural oscillation and functional connectivity patterns in late-life depression | |
| Piano et al. | Sleep-related modifications of EEG connectivity in the sensory-motor networks in Huntington Disease: An eLORETA study and review of the literature | |
| Opie et al. | Transcranial magnetic stimulation-electroencephalography measures of cortical neuroplasticity are altered after mild traumatic brain injury | |
| Akkol et al. | Intracranial electroencephalography reveals selective responses to cognitive stimuli in the periventricular heterotopias | |
| De Pieri et al. | Resting-state EEG and MEG gamma frequencies in schizophrenia: a systematic review and exploratory power-spectrum metanalysis | |
| Roberts et al. | Towards biomarkers for autism spectrum disorder: contributions of magnetoencephalography (MEG) | |
| Sulejmanpasic et al. | The correlation of PANSS scores and P100 latency in patients with schizophrenia and migrene hedache using visual evoked potentials (VEPS) according to gender and age | |
| 中西翔一郎 | Abnormal phase entrainment of low-and high-gamma-band auditory steady-state responses in schizophrenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |